The Latest in Non-Hodgkin Lymphoma Hub

Novel options for treating hairy cell leukemia

October 2, 2018

Indolent Lymphoma

FDA lifts partial hold on tazemetostat trials

September 30, 2018

Aggressive Lymphomas

Prognostic factors guide mantle cell treatment decisions

September 28, 2018

Aggressive Lymphomas

Real-world clues for optimal sequencing of CLL novel agents

September 25, 2018

Indolent Lymphoma

Outpatient lenalidomide/rituximab yields long-term MCL remission

September 25, 2018

Aggressive Lymphomas

FDA approves new drug for CLL/SLL and follicular lymphoma

September 25, 2018

Indolent Lymphoma

NICE looks likely to reject use of Kymriah for DLBCL

September 24, 2018

Aggressive Lymphomas

Best practices defined for proton therapy in mediastinal lymphomas

September 18, 2018

Aggressive Lymphomas

Be wary of watchful waiting in follicular lymphoma

September 16, 2018

Indolent Lymphoma

Pruritus linked to wide variety of cancers

September 16, 2018

Indolent Lymphoma

Venetoclax label now includes MRD data

September 12, 2018

Aggressive Lymphomas

TP53 mutation plus complex karyotype equals poor prognosis

September 10, 2018

Aggressive Lymphomas

ASCO updates guidance on prophylaxis for adults with cancer-related immunosuppression

September 7, 2018

Indolent Lymphoma

Novartis nabs first CAR T approval in Canada

September 7, 2018

Aggressive Lymphomas

RESONATE-2 update: First-line ibrutinib has sustained efficacy in older CLL patients

September 6, 2018

Aggressive Lymphomas